The key players such as Inozyme Pharma and others can create a significant positive shift in the Pseudoxanthoma Elasticum market size in the upcoming years. The current pipeline of Pseudoxanthoma Elasticum is restricted, with only a few companies working on this indication. Hence, it is an opportunity for other companies to enter the market and grab a significant market share.
DelveInsight’s “Pseudoxanthoma Elasticum Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pseudoxanthoma Elasticum market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Pseudoxanthoma Elasticum market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pseudoxanthoma Elasticum: An Overview
Pseudoxanthoma elasticum (PXE) is the name given to a group of connective tissue disorders that affect the elastic tissue of the skin, blood vessels, and eyes. PXE is also known as Gronblad–Strandberg syndrome. Individuals with PXE have distinctive skin lesions, changes in blood vessels, and eye abnormalities. These may vary in distribution and severity.
The basic fault in PXE appears to relate to genetic abnormalities on chromosome 16p13.1. The disease involves the transporter genes MRP6 or ABCC6 in at least some affected families. There is good evidence that collagen and ground substances are abnormal in affected individuals. Calcium accumulates in abnormal elastic fibers in the skin, blood vessels, eyes, and heart.
The skin lesions of PXE are characteristic. They consist of small, yellowish bumps in rows or a lacy pattern, which may join to make large patches. The skin is soft, lax, and slightly wrinkled. The patches may be somewhat pebbly in appearance, described as cobblestoned.
Pseudoxanthoma Elasticum Market Key Facts
According to the National Organization of Rare Disorders (NORD, n.d.), the true estimates of PXE are not known in any population. Likely, many individuals with PXE have not been diagnosed, particularly people with mild signs of PXE or those whose signs are not typical.
According to Germain (2017), the clinical prevalence of PXE was estimated at between 1 per 100,000 and 1 per 25,000, with slight female predominance.
According to an article by Uitto et al. (2015), the precise prevalence of PXE is currently unknown, but estimates suggest a prevalence of 1 in 50,000 in the United States. With the same global prevalence, there could be as many as 150,000 patients affected by PXE worldwide. Even this number may be an underestimate since PXE, like many genetic conditions, has variable expressivity and its milder forms often remain undiagnosed for years or even for a lifetime.
According to Orphanet (n.d.), the overall prevalence of PXE is estimated at between 1/40,000 and 1/100,000 in the general population, with female predominance (female to male ratio 4:1); however, the reason for the female predominance is unknown.
Pseudoxanthoma Elasticum Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pseudoxanthoma Elasticum market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pseudoxanthoma Elasticum market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pseudoxanthoma Elasticum Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Pseudoxanthoma Elasticum Epidemiology, Segmented as –
Total Prevalent Cases of Pseudoxanthoma Elasticum in the 7MM [2019–2032]
Diagnosed and Treatable Cases of Pseudoxanthoma Elasticum in the 7MM [2019–2032]
Gender-specific Prevalent Cases of Pseudoxanthoma Elasticum in the 7MM [2019–2032]
Prevalent Cases of Pseudoxanthoma Elasticum Classified Based on Symptoms Manifestations in the 7MM [2019–2032]
Pseudoxanthoma Elasticum Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pseudoxanthoma Elasticum market or expected to be launched during the study period. The analysis covers the Pseudoxanthoma Elasticum market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pseudoxanthoma Elasticum pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pseudoxanthoma Elasticum Market Will Evolve and Grow by 2032 @
Pseudoxanthoma Elasticum Therapeutics Analysis
Inozyme Pharma’s INZ-701 is in clinical development for the potential treatment of various disorders linked primarily to mutations in the ENPP1 and ABCC6 genes. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency –two rare abnormal mineralization disorders. Inozyme is conducting Phase I/II trials for patients suffering from ABCC6 Deficiency.
INZ-701 has received Orphan Drug designations from both the US FDA and EMA for the treatment of Pseudoxanthoma Elasticum. The therapy has also received Fast Track designation and rare pediatric disease designation from the US FDA for ENPP1 Deficiency.
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pseudoxanthoma Elasticum Competitive Intelligence Analysis
4. Pseudoxanthoma Elasticum Market Overview at a Glance
5. Pseudoxanthoma Elasticum Disease Background and Overview
6. Pseudoxanthoma Elasticum Patient Journey
7. Pseudoxanthoma Elasticum Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Pseudoxanthoma Elasticum Treatment Algorithm, Current Treatment, and Medical Practices
9. Pseudoxanthoma Elasticum Unmet Needs
10. Key Endpoints of Pseudoxanthoma Elasticum Treatment
11. Pseudoxanthoma Elasticum Marketed Products
12. Pseudoxanthoma Elasticum Emerging Drugs and Latest Therapeutic Advances
13. Pseudoxanthoma Elasticum Seven Major Market Analysis
14. Attribute Analysis
15. Pseudoxanthoma Elasticum Market Outlook (In US, EU5, and Japan)
16. Pseudoxanthoma Elasticum Access and Reimbursement Overview
17. KOL Views on the Pseudoxanthoma Elasticum Market
18. Pseudoxanthoma Elasticum Market Drivers
19. Pseudoxanthoma Elasticum Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
The global Holter Monitor Market is expected to grow at a CAGR of 6.13% during the forecast period (2023 to 2028). The Holter Monitor Market is anticipated to grow owing to the rising burden of various cardiovascular disorders which leads to abnormal heart rhythms such as atrial fibrillation, and heart palpitations, among others that may require monitoring through Holter Monitor. Additionally, a rise in sedentary lifestyles and lifestyle-associated disorders that increase the risk of developing CVD many folds is also expected to increase the demand for Holter Monitor in the upcoming years.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States